1. Home
  2. TMQ vs ASMB Comparison

TMQ vs ASMB Comparison

Compare TMQ & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

SELL

Current Price

$1.83

Market Cap

579.8M

ML Signal

SELL

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

SELL

Current Price

$21.22

Market Cap

512.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TMQ
ASMB
Founded
2004
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.8M
512.1M
IPO Year
2012
2010

Fundamental Metrics

Financial Performance
Metric
TMQ
ASMB
Price
$1.83
$21.22
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$6.64
★ $51.20
AVG Volume (30 Days)
★ 1.4M
229.1K
Earning Date
10-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.78
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.48
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$19.20
52 Week High
$7.25
$39.71

Technical Indicators

Market Signals
Indicator
TMQ
ASMB
Relative Strength Index (RSI) 29.05 49.45
Support Level N/A $19.25
Resistance Level $2.35 $21.65
Average True Range (ATR) 0.14 1.23
MACD 0.00 0.33
Stochastic Oscillator 0.93 59.89

Price Performance

Historical Comparison
TMQ
ASMB

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: